Pre-Clinical Immune Response And Safety Evaluation Of The Protein Subunit Vaccine Nanocovax For COVID-19
Tran, T. N. M.; May, B.; Ung, T. T.; Nguyen, M. K.; Nguyen, T. T.; Dinh, V. L.; Tran, T. V.; Khong, H.; Nguyen, T. T.; Hua, H. Q. H.; Nguyen, V. A.; Ha, T. P.; Phan, D. L.; Nguyen, T. A.; Bui, T. N.; Tu, T. M.; Nguyen, T. T.; Le, T. H.; Dong, T. L.; Huynh, T. H.; Truong, C. T.; Nie, L.; Cao, M. N.; Nguyen, D. K.; Trinh, T. H.; Do, M. S.
Show abstract
The Coronavirus disease-2019 (COVID-19) pandemic caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), has become a dire global health concern. The development of vaccines with high immunogenicity and safety is crucial for control of the global COVID-19 pandemic and prevention of further illness and fatalities. Here, we report development of SARS-CoV-2 vaccine candidate, Nanocovax, based on recombinant protein production of the extracellular (soluble) portion of the S protein of SARS-CoV-2. The results showed that Nanocovax induced high levels of S protein-specific IgG, as well neutralizing antibody in three animal models including Balb/C mice, Syrian hamsters, and non-human primate (Macaca leonina). In addition, the viral challenge study using the hamster model showed that Nanocovax protected the upper respiratory tract from SARS-CoV-2 infection. No adverse effects were induced by Nanocovax in swiss mice (Musmusculus var. Albino), Rats (Rattus norvegicus), and New Zealand rabbits. These pre-clinical results indicated that Nanocovax is safe and effective.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Mice immunized with the vaccine candidate HexaPro spike produce neutralizing antibodies against SARS-CoV-2 96%
- Immunogenicity and adverse events of priming with inactivated whole SARS-CoV-2 vaccine (CoronaVac) followed by boosting the ChAdOx1 nCoV-19 vaccine 96%
- A Whole Virion Vaccine for COVID-19 Produced Via a Novel Inactivation Method: Results from Animal Challenge Model Studies 95%
Similar papers in this journal
- Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates 98%
- Recombinant SARS-CoV-2 RBD molecule with a T helper epitope as a built in adjuvant induces strong neutralization antibody response 97%
- Immunogenic Potential of DNA Vaccine candidate, ZyCoV-D against SARS-CoV-2 in Animal Models 97%
Similar papers in this journal
- Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo 95%
- In silico analysis and in planta production of recombinant ccl21/IL1β protein and characterization of its in vitro anti-tumor and immunogenic activity 95%
- Intranasal Nanoemulsion Adjuvanted S-2P Vaccine Demonstrates Protection in Hamsters and Induces Systemic, Cell-Mediated and Mucosal Immunity in Mice 95%
Similar papers in this journal
- Comparison of Wild Type DNA Sequence of Spike Protein from SARS-CoV-2 with Optimized Sequence on The Induction of Protective Responses Against SARS-Cov-2 Challenge in Mouse Model 96%
- SARS-CoV-2 RBD219-N1C1: A Yeast-Expressed SARS-CoV-2 Recombinant Receptor-Binding Domain Candidate Vaccine Stimulates Virus Neutralizing Antibodies and T-cell Immunity in Mice 95%
- Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine 94%
Similar papers in this journal
- Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response 96%
- Omicron booster in ancestral strain vaccinated mice augments protective immunities against both the Delta and Omicron variants 95%
- BNT162b2, mRNA-1273, and Sputnik V vaccines induce comparable immune responses on a par with severe course of COVID-19 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.